MGC Pharmaceuticals Ltd.
PDMR Notification
11 January 2024
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') wishes to advise that the following Persons Discharging Managerial Responsibilities (PDMR) have dealt with shares in MGC Pharma, and this notification is made in accordance the UK Market Abuse Regulations.
The shares subject of this notice were issued to the PDMR's as part of their working contracts and as consideration for services rendered in lieu of cash payments
| 1 | Details of the person discharging managerial responsibilities/person closely associated
| ||||
| (a) | Name | Amir Polak | |||
| 2 | Reason for the notification
| ||||
| (a) | Position
| Chief Pharmaceutical Development Officer | |||
| (b) | Initial notification/amendment
| Initial | |||
| (c) | If amendment: reason
| n/a | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| | Full name of entity | MGC Pharmaceuticals Limited
| |||
| | Legal Entity Identifier Code | 213800HRE3FQJ6RK4H10
| |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
| ||||
| (a) | Description of the financial instrument, type of instrument | Fully Paid Ordinary Shares | |||
| (b) | Identification Code (ISIN)
| AU000000MXC6 | |||
| (c) | Nature of transaction | Shares issued as part of their working contracts and as consideration for services rendered in lieu of cash payments | |||
| (d) | Currency | Price | Volume | Total | |
| | AUD | A$0.55 | 600,000 | A$330,000 | |
| | Aggregated information | ||||
| | AUD | A$0.55 | 600,000 | A$330,000 | |
| (e) | Date of transaction
| 10 January 2024 | |||
| (f) | Place of transaction
| Outside a trading venue | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated
| ||||
| (a) | Name | Sabina Suljakovic | |||
| 2 | Reason for the notification
| ||||
| (a) | Position
| Vice President of Global Quality | |||
| (b) | Initial notification/amendment
| Initial | |||
| (c) | If amendment: reason
| n/a | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| | Full name of entity | MGC Pharmaceuticals Limited
| |||
| | Legal Entity Identifier Code | 213800HRE3FQJ6RK4H10
| |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
| ||||
| (a) | Description of the financial instrument, type of instrument | Fully Paid Ordinary Shares | |||
| (b) | Identification Code (ISIN)
| AU000000MXC6 | |||
| (c) | Nature of transaction | Shares issued as part of their working contracts and as consideration for services rendered in lieu of cash payments | |||
| (d) | Currency | Price | Volume | Total | |
| | AUD | A$0.55 | 17,000 | A$9,350 | |
| | Aggregated information | ||||
| | AUD | A$0.55 | 17,000 | A$9,350 | |
| (e) | Date of transaction
| 10 January 2024 | |||
| (f) | Place of transaction
| Outside a trading venue | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated
| ||||
| (a) | Name | Yair Tal | |||
| 2 | Reason for the notification
| ||||
| (a) | Position
| Chief Information Security Officer | |||
| (b) | Initial notification/amendment
| Initial | |||
| (c) | If amendment: reason
| n/a | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| | Full name of entity | MGC Pharmaceuticals Limited
| |||
| | Legal Entity Identifier Code | 213800HRE3FQJ6RK4H10
| |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
| ||||
| (a) | Description of the financial instrument, type of instrument | Fully Paid Ordinary Shares | |||
| (b) | Identification Code (ISIN)
| AU000000MXC6 | |||
| (c) | Nature of transaction | Shares issued as part of their working contracts and as consideration for services rendered in lieu of cash payments | |||
| (d) | Currency | Price | Volume | Total | |
| | AUD | A$0.55 | 300,000 | A$165,000 | |
| | Aggregated information | ||||
| | AUD | A$0.55 | 300,000 | A$165,000 | |
| (e) | Date of transaction
| 10 January 2024 | |||
| (f) | Place of transaction
| Outside a trading venue | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated
| ||||
| (a) | Name | Yifat Steuer | |||
| 2 | Reason for the notification
| ||||
| (a) | Position
| Chief Operating Officer and Deputy CEO | |||
| (b) | Initial notification/amendment
| Initial | |||
| (c) | If amendment: reason
| n/a | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| | Full name of entity | MGC Pharmaceuticals Limited
| |||
| | Legal Entity Identifier Code | 213800HRE3FQJ6RK4H10
| |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
| ||||
| (a) | Description of the financial instrument, type of instrument | Fully Paid Ordinary Shares | |||
| (b) | Identification Code (ISIN)
| AU000000MXC6 | |||
| (c) | Nature of transaction | Shares issued as part of their working contracts and as consideration for services rendered in lieu of cash payments | |||
| (d) | Currency | Price | Volume | Total | |
| | AUD | A$0.55 | 1,100,000 | A$605,000 | |
| | Aggregated information | ||||
| | AUD | A$0.55 | 1,100,000 | A$605,000 | |
| (e) | Date of transaction
| 10 January 2024 | |||
| (f) | Place of transaction
| Outside a trading venue | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated
| ||||
| (a) | Name | Rowan Harland | |||
| 2 | Reason for the notification
| ||||
| (a) | Position
| Company Secretary | |||
| (b) | Initial notification/amendment
| Initial | |||
| (c) | If amendment: reason
| n/a | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| | Full name of entity | MGC Pharmaceuticals Limited
| |||
| | Legal Entity Identifier Code | 213800HRE3FQJ6RK4H10
| |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
| ||||
| (a) | Description of the financial instrument, type of instrument | Fully Paid Ordinary Shares | |||
| (b) | Identification Code (ISIN)
| AU000000MXC6 | |||
| (c) | Nature of transaction | Shares issued as part of their working contracts and as consideration for services rendered in lieu of cash payments | |||
| (d) | Currency | Price | Volume | Total | |
| | AUD | A$0.55 | 7,000 | A$3,850 | |
| | Aggregated information | ||||
| | AUD | A$0.55 | 7,000 | A$3,850 | |
| (e) | Date of transaction
| 10 January 2024 | |||
| (f) | Place of transaction
| Outside a trading venue | |||
| 1 | Details of the person discharging managerial responsibilities/person closely associated
| ||||
| (a) | Name | Ana Arhar Oblak | |||
| 2 | Reason for the notification
| ||||
| (a) | Position
| Group Financial Controller | |||
| (b) | Initial notification/amendment
| Initial | |||
| (c) | If amendment: reason
| n/a | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| | Full name of entity | MGC Pharmaceuticals Limited
| |||
| | Legal Entity Identifier Code | 213800HRE3FQJ6RK4H10
| |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted
| ||||
| (a) | Description of the financial instrument, type of instrument | Fully Paid Ordinary Shares | |||
| (b) | Identification Code (ISIN)
| AU000000MXC6 | |||
| (c) | Nature of transaction | Shares issued as part of their working contracts and as consideration for services rendered in lieu of cash payments | |||
| (d) | Currency | Price | Volume | Total | |
| | AUD | A$0.55 | 10,000 | A$5,500 | |
| | Aggregated information | ||||
| | AUD | A$0.55 | 10,000 | A$5,500 | |
| (e) | Date of transaction
| 10 January 2024 | |||
| (f) | Place of transaction
| Outside a trading venue | |||
-Ends-
Authorised for release by the Managing Director, for further information please contact:
| MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director +61 8 6555 2950 | MGC Pharmaceuticals Ltd Rowan Harland Company Secretary +61 8 6555 2950
|
| UK IR/PR Advisers IFC Advisory Graham Herring / Tim Metcalfe / Zach Cohen +44 203 934 6630 | UK Brokers Oberon Capital Aimee McCusker / Adam Pollock +44 203 179 5300 aimeemccusker@oberoninvestments.com adampollock@oberoninvestments.com |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.